Andrew Booth is CFO at AbCellera Biologics Inc. (ABCL). They have made 6 open-market trades across 1 company since 2021, most recently 2026-08-14.
CIK 0001834411
5 open-market purchases totalling $2.1M since 2021, against 1 sale. Across 5 scored buys the stock is down 2.1% at thirty days, and 0.4 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ABCL | 482,800 | $6.0M |
Shares reported on the most recent Form 4, priced at the 2026-08-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 20% | — |
| Avg Move | -0.6% | -2.1% | — |
| Alpha | -0.1% | +0.4% | — |
| Scored | 5 | 5 | 4 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABCL | BUY | 2026-08-14 | 2026-08-14 | $10.32 | $384K | +8.7% | -0.8% | — |
| ABCL | BUY | 2026-02-27 | 2026-02-27 | $3.42 | $146K | +5.2% | -5.2% | +65.4% |
| ABCL | BUY | 2023-05-26 | 2023-05-26 | $6.85 | $99K | +3.5% | -0.1% | -20.5% |
| ABCL | BUY | 2022-05-12 | 2022-05-16 | $5.79 | $492K | -6.3% | +15.9% | +69.3% |
| ABCL | BUY | 2021-11-11 | 2021-11-15 | $14.71 | $993K | -14.2% | -20.3% | -41.7% |
| ABCL | SELL | 2021-06-09 | 2021-06-10 | $25.50 | $30.6M | -13.3% | -26.8% | -28.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.